MedTrace Logo

Hepcidin as a Predictor for the IVI Mediated Increase in Haemoglobin Levels

NCT04263571 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-10-08

No results posted yet for this study

Summary

The study is a multidisciplinary study, which involves all kind of medical specialties. Patients, who are scheduled for elective surgery, will be seen at a multidisciplinary anaesthesia/Patient Blood Management (PBM) clinic and screened for anaemia prior to surgery. Anaemic patients will eventually be treated with 500mg of iron isomaltoside.

Conditions

Sponsors & Collaborators

  • Pharmacosmos A/S

    collaborator INDUSTRY

  • University Hospital Muenster

    collaborator OTHER

  • Goethe University

    lead OTHER

Principal Investigators

  • Andrea U Steinbicker, Prof Dr MPH · Johann Wolfgang Goethe-University, Dept. of Anesthesiology, Intensive Care and Pain Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-12
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04263571 on ClinicalTrials.gov